`_________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_________________________________
`
`
`NOVEN PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`_________________________________
`
`
`Inter Partes Review No.: 2014-00549
`
`U.S. Patent 6,316,023
`
`
`
`PETITIONER’S EXHIBIT LIST 1
`
`
`
`
`
`Pursuant to 37 C .F.R. §42.63(e), Petitioner Noven submits the following
`
`current exhibit list.
`
`Noven
`
`.
`
`.
`
`Ex. 1001
`
`U-S- Patent NO- 6,316,023, issued November 13, 2001
`
`published September 18, 1985 (“Kissel”)
`
`UK Patent Application GB 2,203,040 A, to Enz, published
`
`October 12, 1988 (“Enz”)
`
`Handbook of Pharmaceutical Excipients, A. Wade and P. J.
`
`Weller (eds.) 1994, 2nd Edition, The Pharmaceutical Press
`
`London (the “Handbook”)
`
`Japanese Patent Application Publication No. JP 59-184121 to
`
`Sasaki et al., published October 19, 1984
`
`Certified English Translation of Japanese Patent Application
`
`Publication No. JP 59—184121 to Sasaki et a1. (“Sasaki”)
`
`PCT Publication No. W0 95/024172 to Ebert et al, published
`
`September 14, 1995 (“Ebert”)
`
`European Patent Application No. 0155 229 A2 to Kissel et al.,
`
`
`
`Ex. 1008 U.S. Patent No. 4,948,807 (“Rosin”)
`
`Ex. 1009
`
`Elmalem et al. 1991, Neuropharmacology 30: 1059-1064
`
`(“Elmalem”)
`
`Ex. 1010 Declaration of Agis Kydonieus, Ph.D.
`
`Ex. 1011 Declaration of Christian Schöneich, Ph.D.
`
`Ex. 1012
`
`“Safety/Tolerability Trial of SDZ ENA 713 in Patients with
`
`Probable Alzheimer’s Disease,” John J. Sramek et al., Life
`
`Sciences, Vol. 58, No. 15, pp. 1201-1207 (1996) (“Sramek”)
`
`Ex. 1013
`
`“New acetylcholinesterase inhibitor shows promise in largest
`
`Alzheimer’s trial to date,” Formulary, Vol. 32, Dec. 1997
`
`(“Formulary Article”)
`
`Ex. 1014
`
`ICH Topic Q 1 A, Stability Testing Guidelines: Stability
`
`Testing of New Drug Substances and Products
`
`(CPMP/ICH/380/95)
`
`2
`
`
`
`Ex. 1015
`
`Connors, Amidon, & Stella, Oxidation and Photolysis in
`
`Chemical Stability of Pharmaceuticals – A Handbook for
`
`Pharmacists (2nd Edition), John Wiley & Sons, NY (1986), pp.
`
`82-114
`
`Ex. 1016 Howard C. Ansel, Introduction to Pharmaceutical Dosage
`
`Forms, 4th Edition, Lea & Febiger, Philadelphia (1985), pp.
`
`83-116
`
`Ex. 1017 Ho-Leung Fung, Chapter 7 – Chemical Kinetics and Drug
`
`Stability in MODERN PHARMACEUTICS (G.S. Banker and
`
`C.T. Rhodes, eds.), Marcel Dekker, NY (1979), pp. 227-62
`
`Ex. 1018
`
`Carey & Sundberg, ADVANCED ORGANIC CHEMISTRY,
`
`Part A: Structure and Mechanism, 3rd Edition (Plenum Press,
`
`NY), pp. 651-727 (1990)
`
`Ex. 1019 Miguel-Hidalgo, J., 2000, Current Opinion in CPNS
`
`Investigations Drugs, 2000 2(4):438-453
`
`Ex. 1020
`
`Boccardi G. et al. Photochemical Iron(III)-Mediated
`
`Autoxidation of Dextromethorphan. Chemical &
`
`Pharmaceutical Bulletin. Vol. 37, 308–310 (1989)
`
`3
`
`
`
`Ex. 1021
`
`Bateman, L., Olefin Oxidation, Quarterly Review (1954) Vol.
`
`8, pp. 147–167
`
`Ex. 1022
`
`Linnell, R.H., The Oxidation of Nicotine. I. Kinetics of the
`
`Liquid Phase Reaction Near Room Temperature. Tobacco
`
`Science, Vol. 4, pp. 89–91 (1960)
`
`Ex. 1023
`
`Resume/ Curriculum Vitae of Agis Kydonieus, Ph.D.
`
`Ex. 1024
`
`Resume/ Curriculum Vitae of Christian Schöneich, Ph.D.
`
`Ex. 1025 U.S. Patent No. 5,602,176, issued Feb. 11, 1997
`
`Ex. 1026
`
`Redacted Copy of Bench Trial Transcript (Day 1). C.A. No.
`
`13-527, D.I. 154 (D. Del).
`
`Ex. 1027
`
`Redacted Copy of Bench Trial Transcript (Day 2). C.A. No.
`
`13-527, D.I. 155 (D. Del).
`
`Ex. 1028
`
`Redacted Copy of Bench Trial Transcript (Day 3). C.A. No.
`
`13-527, D.I. 156 (D. Del).
`
`Ex. 1029 U.S. Patent No. 5,061,480. [Not Filed]
`
`Ex. 1030
`
`Transcript of 1/13/2015 Deposition of Dr. Agis Kydonieus
`
`4
`
`
`
`
`
`
`
`Dated: January 20, 2015
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/Steven J. Lee/
`Steven J. Lee (Reg. No. 31,272)
`Michael K. Levy (Reg. No. 40,699)
`KENYON & KENYON LLP
`One Broadway
`New York, NY 10004-1007
`Tel: 212-425-7200
`Fax: 212-425-5288
`Counsel for Petitioner Noven Pharmaceuticals,
`Inc.
`
`5
`
`
`
`CERTIFICATE OF SERVICE
`
` I
`
` certify pursuant to 37 C.F.R. §42.6(e) that a copy of Noven’s current
`
`Exhibit List and copies of Exhibits 1026, 1027, 1028, and 1029, were served by
`
`hand on January 13, 2015 to Charlotte C. Jacobsen, Esq., of Fitzpatrick, Cella,
`
`Harper & Scinto, 1290 Avenue of the Americas, New York, NY 10104-3800,
`
`pursuant to 37 C.F.R. §42.63(e) and §42.53(f)(3). I also certify pursuant to 37
`
`C.F.R. §42.6(e) that a copy of the foregoing Exhibit List 1 and copies of Exhibits
`
`1026, 1027, 1028, 1029, and 1030, were served electronically on January 20, 2015
`
`pursuant to 37 C.F.R. §42.63(e) to counsel for Patent Owners at the following
`
`email address: ExelonPatchIPR@fchs.com.
`
`
`
`
`
`Dated: January 20, 2015
`
`
`
`
`
`
`
`
`
`/Christopher J. Coulson/
`Christopher J. Coulson (Reg. No. 61,771)
`KENYON & KENYON LLP
`One Broadway
`New York, NY 10004-1007
`Tel: 212-425-7200
`Fax: 212-425-5288
`Counsel for Petitioner Noven Pharmaceuticals,
`Inc.
`
`6
`
`